Research & Development
"Hundreds of dedicated experts and partner organizations have teamed up with MMV to build the largest pipeline of antimalarials in history."
Dr Dennis Schmatz,
Chair of Drug Discovery, MMV ESAC
Existing antimalarials have complex dosing regimes and target mainly falciparum malaria. MMV is seeking both a one-dose cure for falciparum malaria and a radical cure of vivax (relapsing) malaria.
Emerging drug resistance to artemisinin is a warning sign that we urgently need new classes of antimalarials. MMV is working to find ways to overcome resistance to current and future medicines.
New medicines that block the transmission of the parasite from patient to patient are vital if we are to defeat malaria. MMV is working to accelerate the development of these medicines.
Find all the information and resources that you need to work with MMV.
MMV's Target Product Profiles & Target Candidate Profiles highlight the needs in designing the next generation of medicines for malaria control and eradication.
Learn more about our open source projects: The Pathogen Box, the Malaria Box and Open Source Drug Discovery (OSDD).
These new guides share free solutions to common problems faced by medicinal and computational chemists working in the not-for-profit arena.
- 20 November 2015
Pyramax® Granules becomes first paediatric antimalarial to receive EMA article 58 positive scientific opinion20 November 2015
- 08 November 2015
- 05 November 2015
- 23 October 2015